Co-Diagnostics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.87M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $166.13K | $-1.46 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $150.00K | $-4.06 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $100.00K | $-0.16 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $200.00K | $-0.23 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $100.00K | $-0.24 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $600.00K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | After market close | – | – | – |
Press releases
Announcements Co-Diagnostics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LAKE CITY, Dec. 30, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”),
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. to Participate in the Lytham
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
have entered into the Amended and Restated Equity Distribution Agreement dated April 25, 2025, with Piper Sandler and Clear Street LLC
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Reports Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance
Other events · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Full Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Full Year 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Solid First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Full Year 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Authorization of $30 Million Share Repurchase Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Continued Strength in Third Quarter 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K